[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Briacell Therapeutics Corp. WT (BCTXZ)

Briacell Therapeutics Corp. WT (BCTXZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,312 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0648 +54.32%
on 06/11/26
0.1100 -9.09%
on 07/07/26
+0.0199 (+24.84%)
since 06/08/26
3-Month
0.0602 +66.11%
on 06/05/26
0.1515 -33.99%
on 04/20/26
-0.0500 (-33.33%)
since 04/08/26
52-Week
0.0551 +81.49%
on 03/09/26
0.9750 -89.74%
on 07/09/25
-0.9600 (-90.57%)
since 07/08/25

Most Recent Stories

More News
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

Charles River Associates (CRA) to evaluate epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer in the US Kaleio to support brand strategies...

BCT.TO : 5.27 (+7.11%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1000 (unch)
BCTXL : 0.9500 (+11.76%)
CRAI : 153.91 (-0.95%)
BCTX : 3.70 (+6.02%)
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

Agreement supports potential commercial readiness for Bria-IMT using Uneedle’s proprietary microneedle technology for intradermal administration  Technology is currently used in BriaCell’s pivotal...

BCT.TO : 5.27 (+7.11%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1000 (unch)
BCTXL : 0.9500 (+11.76%)
BCTX : 3.70 (+6.02%)
BriaCell Therapeutics Announces Closing of Offering

PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...

BCT.TO : 5.27 (+7.11%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1000 (unch)
BCTXL : 0.9500 (+11.76%)
BCTX : 3.70 (+6.02%)
BriaCell Presents Positive Clinical Data at ASCO 2026

Final Bria-IMT™ Phase 2 data show 55% >1 year and 27% >2-year survival in heavily pre-treated metastatic breast cancer (MBC) patients treated with Bria-IMT regimen selected for Phase 3 TWiST...

BCT.TO : 5.27 (+7.11%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1000 (unch)
BCTXL : 0.9500 (+11.76%)
BCTX : 3.70 (+6.02%)
BriaCell Therapeutics Announces Pricing of Offering

PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...

BCT.TO : 5.27 (+7.11%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1000 (unch)
BCTXL : 0.9500 (+11.76%)
BCTX : 3.70 (+6.02%)
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Independent DSMB has identified no safety concerns, to date, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor Sixth consecutive positive...

BCT.TO : 5.27 (+7.11%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1000 (unch)
BCTXL : 0.9500 (+11.76%)
BCTX : 3.70 (+6.02%)
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) Positive Quality of Life (QOL) data from the ongoing Phase 3 study in heavily pre-treated metastatic...

BCT.TO : 5.27 (+7.11%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1000 (unch)
BCTXL : 0.9500 (+11.76%)
BCTX : 3.70 (+6.02%)
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast cancer Bria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian...

BCT.TO : 5.27 (+7.11%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1000 (unch)
BCTXL : 0.9500 (+11.76%)
BCTX : 3.70 (+6.02%)
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

Bria-PROS+ is BriaCell’s next generation personalized off-the-shelf immunotherapy for prostate cancer Immune stimulating components of Bria-PROS+ enhance anti-tumor responses BriaCell has completed...

BCT.TO : 5.27 (+7.11%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1000 (unch)
BCTXL : 0.9500 (+11.76%)
BCTX : 3.70 (+6.02%)
BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Virginia (UVA) Comprehensive Cancer Center, Baptist Health South Florida, and...

BCT.TO : 5.27 (+7.11%)
BCTXW : 0.0009 (-57.14%)
BCTXZ : 0.1000 (unch)
BCTXL : 0.9500 (+11.76%)
BCTX : 3.70 (+6.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.